BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 23813697)

  • 21. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines.
    Biancolella M; Valentini A; Minella D; Vecchione L; D'Amico F; Chillemi G; Gravina P; Bueno S; Prosperini G; Desideri A; Federici G; Bernardini S; Novelli G
    Invest New Drugs; 2007 Oct; 25(5):491-7. PubMed ID: 17636412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
    Hsieh JT; Chen SC; Yu HJ; Chang HC
    Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.
    Masoodi KZ; Ramos Garcia R; Pascal LE; Wang Y; Ma HM; O'Malley K; Eisermann K; Shevrin DH; Nguyen HM; Vessella RL; Nelson JB; Parikh RA; Wang Z
    Endocrinology; 2013 Jul; 154(7):2296-307. PubMed ID: 23671262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
    di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
    J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation.
    Hamid AR; Verhaegh GW; Smit FP; van Rijt-van de Westerlo C; Armandari I; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    J Urol; 2015 Mar; 193(3):1023-9. PubMed ID: 25242390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
    Opoku-Acheampong AB; Nelsen MK; Unis D; Lindshield BL
    PLoS One; 2012; 7(1):e29068. PubMed ID: 22242155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer.
    Seok J; Kwak HJ; Kwak Y; Lee M; Park KS; Kim A; Cho SG
    J Transl Med; 2023 Feb; 21(1):129. PubMed ID: 36800968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.
    Mostaghel EA; Geng L; Holcomb I; Coleman IM; Lucas J; True LD; Nelson PS
    Cancer Res; 2010 Feb; 70(4):1286-95. PubMed ID: 20124490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
    Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
    Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
    Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of dihydrotestosterone in benign prostatic hyperplasia.
    Carson C; Rittmaster R
    Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central 5-alpha reduction of testosterone is required for testosterone's inhibition of the hypothalamo-pituitary-adrenal axis response to restraint stress in adult male rats.
    Handa RJ; Kudwa AE; Donner NC; McGivern RF; Brown R
    Brain Res; 2013 Sep; 1529():74-82. PubMed ID: 23880372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5α-reductase type 1 modulates insulin sensitivity in men.
    Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
    J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
    Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
    J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
    Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
    Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.